Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to prese...
For the treatment of mild to moderate essential or primary hypertension . Effective as most first-line antihypertensives when used as monotherapy .
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.